Select Language
BCMA
BCMA Overview
| English Name | B-cell maturation protein | Approved Drugs | 8 |
| Drugs in Clinical Trials | 151 | Target Synonym | B-Cell Maturation Protein，B-Cell Maturation Factor，B Cell Maturation Antigen，CD269 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 17，TNFRSF17，TNFRSF13A，CD269，BCM，BCMA，TNF Receptor Superfamily Member 17，Tumor Necrosis Factor Receptor Superfamily， Member 17，B-Cell Maturation Antigen |
| Highest Development Stage | Approved | ||
| English Name | B-cell maturation protein |
| Target Synonym | B-Cell Maturation Protein，B-Cell Maturation Factor，B Cell Maturation Antigen，CD269 Antigen，Tumor Necrosis Factor Receptor Superfamily Member 17，TNFRSF17，TNFRSF13A，CD269，BCM，BCMA，TNF Receptor Superfamily Member 17，Tumor Necrosis Factor Receptor Superfamily， Member 17，B-Cell Maturation Antigen |
| Approved Drugs | 8 |
| Drugs in Clinical Trials | 151 |
| Highest Development Stage | Approved |
BCMA Product List
- Product Category
Protein (31)Antibody (1)Beads (1)Cell Grade Beads (2)Kits (1)Cell (3)
- Product Status
Launched (39)
- Species
Human (27)Cynomolgus / Rhesus macaque (5)Mouse (4)Rabbit (1)Rat (1)Canine (1)
- Tag
Fc Tag (4)His Tag (19)Fc Tag & Avi Tag (3)Llama IgG Fc Tag (2)His Tag & Avi Tag (2)Mouse IgG Fc Tag (1)- (8)
- Conjugate
Unconjugated (17)FITC Labeled (3)Biotin-labeled (5)- (7)PE Labeled (2)APC Labeled (2)AF488 Labeled (1)AF647 Labeled (1)AF555 Labeled (1)
Total: 39
- 1
- 2
- 3
- 4
BCMA Background
Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.
BCMA Synonyms
TNFRSF17,CD269,BCM,BCMA
Antibody Project Trading Platform
| Project Name | Project Stage | Molecule Type | Molecule Source | Disease Area | Indication |
|---|---|---|---|---|---|
| BCMA VHH - 01 | Lead | Monoclonal | Nanobody | Hematological Malignancy | Multiple myeloma |
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) | Phase 3 Clinical | The First Affiliated Hospital Of Soochow University | Leukemia; Multiple Myeloma | Details | |
| Anitocabtagene autoleucel | Kite-772; CART-ddBCMA | Phase 3 Clinical | Arcellx Inc | Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Multiple Myeloma; Muscle Weakness; Muscular Diseases; Myasthenia Gravis; Neuromuscular Manifestations | Details |
| Etentamig | TNB-383B; ABBV-383 | Phase 3 Clinical | TeneoOne Inc | Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Waldenstrom Macroglobulinemia | Details |
| Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) | Descartes-08 | Phase 3 Clinical | Cartesian Therapeutics Inc | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Anti-synthetase Syndrome; Dermatomyositis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis | Details |
| GC-012F | AZD0120; GC-012F; GC012F; AZD-0120 | Phase 3 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Amyloidosis; Arthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis; Myositis; Scleroderma, Systemic | Details |
| BCMA/CD19 chimeric antigen receptor (CAR)-modified T cells Therapy(Peking University People's Hospital) | Phase 3 Clinical | Peking University People'S Hospital | Acquired thrombotic thrombocytopenic purpura; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Antiphospholipid Syndrome; Behcet Syndrome; Carcinoma, Transitional Cell; Immunoglobulin G4-Related Disease; Lupus Erythematosus, Systemic; Myositis; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome | Details | |
| Ramantamig | JNJ-79635322; JNJ-5322 | Phase 3 Clinical | Janssen Research & Development Llc | Multiple Myeloma | Details |
| Velinotamig | GR-1803 | Phase 3 Clinical | Chongqing Genrix Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Gamgertamig | CM-336; OM336 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Amyloidosis; Anemia, Hemolytic, Autoimmune; Cytopenia; Evans syndrome; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic; Sjogren's Syndrome; Skin Diseases, Vesiculobullous | Details |
| BCMA CAR-T Cells (Pregene) | PRG-1801; GLPG-5301; DRL-1801 | Phase 2 Clinical | Shenzhen Pregene Biopharma Co Ltd | Immunoglobulin G4-Related Disease; Lupus Nephritis; Multiple Myeloma; Purpura, Thrombocytopenic, Idiopathic | Details |
| Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) | BCMA-CART; HR003 | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma | Details | |
| BCMA CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Multiple Myeloma; Neoplasms, Plasma Cell; Plasmacytoma | Details | |
| Anti-BCMA chimeric antigen receptor T cell therapy (Shanghai Unicar-Therapy Bio-medicine Technology) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Multiple Myeloma | Details | |
| C-CAR088 | C-CAR088 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Multiple Myeloma | Details |
| Orvacabtagene autoleucel | ET140-CAR; MCARH-171; JCARH-125; FCARH-143; ET-140 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center | Multiple Myeloma | Details |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
| KQ-2003 | KQ-2003; KQ2003 | Phase 2 Clinical | Shanghai Keqi Pharmaceutical Technology Co Ltd | Multiple Myeloma; POEMS Syndrome; Solid tumours | Details |
| Pamlectabart tismanitin | HDP101-ATAC; HDM2027; HDP-101 | Phase 2 Clinical | Heidelberg Pharma AG | Hematologic Diseases; Multiple Myeloma; Paraproteinemias | Details |
| Anti BCMA CAR-T cells therapy (Minsk Scientific-Practical Center For Surgery, Transplantation And Hematology) | Phase 2 Clinical | Minsk Scientific-Practical Center For Surgery, Transplantation And Hematology | Multiple Myeloma | Details | |
| Anti-BCMA-CD19 CAR-T cells therapy (Pla General Hospital) | Phase 2 Clinical | Pla General Hospital | Autoimmune Diseases; Immunoglobulin G4-Related Disease | Details | |
| BCMA CAR-T Cell Therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| BCMA/GPRC5D targeting chimeric antigen receptor T cell therapy (Essen Biotech) | Phase 2 Clinical | Essen Biotech | Multiple Myeloma | Details | |
| SL-1703 | SL1703; SL-1703 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Lupus Nephritis; Multiple Myeloma; Scleroderma, Systemic | Details |
| Vonsetamig | REGN-5459 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Lupus Nephritis; Multiple Myeloma; Renal Insufficiency, Chronic | Details |
| QT-019B | QT-019B | Phase 2 Clinical | Hangzhou Qihan Biotechnology Co Ltd | Anemia, Hemolytic, Autoimmune; Autoimmune Diseases; Lupus Erythematosus, Systemic; Myasthenia Gravis | Details |
| anti-BCMA/FcRL5 CAR T cell therapy (Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu) | Multiple Myeloma | Details | |
| ICG-318 | ICG-318; ICG318 | Phase 2 Clinical | Songhe Immunobiological Medical (Shenzhen) Co Ltd | Lupus Erythematosus, Systemic; Lupus Nephritis | Details |
| BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University) | Phase 2 Clinical | The First Affiliated Hospital Of Xiamen University | Multiple Myeloma | Details | |
| BCD-248 | BCD-248 | Phase 2 Clinical | BIOCAD JSC | Multiple Myeloma | Details |
| SENL-103 | SENL-103; S-103 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Amyloidosis; Multiple Myeloma; Multiple Sclerosis; Myasthenia Gravis | Details |
| Nanobody-based biepitope BCMA-targeting CAR-T cells therapy(Tahoe Chunyu Biotechnology) | Phase 2 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details | |
| CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute, The No.2 Clinical Hospital of the Ministry of Health | Multiple Myeloma; Plasmacytoma | Details | |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) | Phase 2 Clinical | Essen Biotech | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Granulomatosis with Polyangiitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Microscopic Polyangiitis; Myositis; Scleroderma, Systemic; Sjogren's Syndrome | Details | |
| Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences) | Phase 2 Clinical | Shahid Beheshti University Of Medical Sciences | Multiple Myeloma | Details | |
| C-CAR168 | C-CAR168 | Phase 2 Clinical | Cellular Biomedicine (Shanghai) Co Ltd | Autoimmune Diseases; Encephalitis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Neuromyelitis Optica; Scleroderma, Systemic; Stiff-Person Syndrome | Details |
| IBI-3003 | IBI3003; IBI-3003 | Phase 2 Clinical | Multiple Myeloma | Details | |
| BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene) | Phase 2 Clinical | Guangzhou Bio-Gene Technology Co Ltd | Multiple Myeloma | Details | |
| CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital) | Phase 2 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details | |
| MBS-314 | MBS-314 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Multiple Myeloma | Details |
| Belantamab | GSK2857914; GSK-2857914 | Phase 2 Clinical | Glaxosmithkline Plc | Autoimmune Diseases; Multiple Myeloma | Details |
| SNC-102 (Shanghai Simnova Biotechnology) | SNC102; CART-BCMA | Phase 2 Clinical | Shanghai Simnova Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA/GPRC5D Bispecific CAR T cell therapy (Shanghai YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma | Details | |
| TQB-2934 | TQB2934; TQB-2934 | Phase 2 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Amyloidosis; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Neoplasms, Plasma Cell | Details |
| CAR-BCMA(Sheba Medical Center) | Phase 2 Clinical | Sheba Medical Center, Israel | Multiple Myeloma | Details | |
| ARI-0002h | ARI-0002h | Phase 2 Clinical | Instituto De Salud Carlos Iii | Multiple Myeloma | Details |
| Descartes-11 | Descartes-11; Descartes-011 | Phase 2 Clinical | Cartesian Therapeutics Inc | Multiple Myeloma | Details |
| BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Multiple Myeloma | Details | |
| F-182112 | F182112; F-182112 | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details | |
| Revlucabtagene Autoleucel | HBI-0101; NXC-201 | Phase 2 Clinical | Hadassah Medical Organization, Immix Biopharma Inc | Arthritis, Rheumatoid; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Multiple Myeloma; Myositis; Scleroderma, Systemic | Details |
| BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Multiple Myeloma; Neoplasms | Details | |
| Podentamig | HPN-217; BCMA TriTAC | Phase 1 Clinical | Abbvie Inc, Harpoon Therapeutics | Multiple Myeloma | Details |
| ACTR 087/SEA BCMA combination therapy | Phase 1 Clinical | Unum Therapeutics Inc | Multiple Myeloma | Details | |
| bb-21217 | bb-21217 | Phase 1 Clinical | Bristol-Myers Squibb Company, Genetix Biotherapeutics Inc | Multiple Myeloma | Details |
| AMG-224 | AMG-224 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| Nendocabtagene onogedleucel | ALLO-715 | Phase 1 Clinical | Cellectis Sa | Multiple Myeloma | Details |
| Alnuctamab | EM-901; BMS-986349; CC-93269 | Phase 1 Clinical | Engmab Ag | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 1 Clinical | The First Affiliated Hospital Of Nanchang University | Multiple Myeloma | Details | |
| Pavurutamab | AMG-701 | Phase 1 Clinical | Amgen Inc | Multiple Myeloma | Details |
| CART-BCMA | MTV-273; CART-BCMA | Phase 1 Clinical | University Of Pennsylvania | Kidney Failure, Chronic; Multiple Myeloma; Rejection of renal transplantation; Renal Insufficiency | Details |
| BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma; Pancytopenia; Waldenstrom Macroglobulinemia | Details | |
| Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) | Phase 1 Clinical | Shengyan Pharmaceutical Technology | Multiple Myeloma | Details | |
| SA102-CAR-T | SA-102; SA102 | Phase 1 Clinical | Wuhan Sian Biotechnology Co Ltd | Multiple Myeloma | Details |
| DXC-009 | DXC-009 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Multiple Myeloma | Details |
| ACLX-001 | ACLX-001 | Phase 1 Clinical | Arcellx Inc | Multiple Myeloma | Details |
| CB-011 | CB-011 | Phase 1 Clinical | Caribou Biosciences Inc | Multiple Myeloma | Details |
| FT-576 | FT-576 | Phase 1 Clinical | Fate Therapeutics Inc, University Of Minnesota | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| P-BCMA-ALLO1 | P-BCMA-ALLO1; RG-6538 | Phase 1 Clinical | Janssen Biotech Inc, Transposagen Biopharmaceuticals Inc | Multiple Myeloma | Details |
| Allogeneic CD19/BCMA-targeted CAR-γδT cell therapy (Institute Of Hematology & Blood Diseases Hospital) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Erythematosus, Systemic; Myositis; Scleroderma, Systemic; Thrombocytopenia | Details | |
| BCMA-Targeted CAR T-Cell therapy (Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University | Multiple Myeloma | Details | |
| CAR BCMA-CD70-T cells therapy (The Fifth Medical Center Of Pla General Hospital) | Phase 1 Clinical | The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) | Neoplasms, Plasma Cell | Details | |
| CD19/BCMA in vivo CAR-T cell therapy (West China Hospital Of Sichuan University) | Phase 1 Clinical | West China Hospital Of Sichuan University | Autoimmune Diseases | Details | |
| O&D-001 | O&D-001 | Phase 1 Clinical | O&D BioTech Group Co Ltd | Multiple Myeloma | Details |
| Autologous CD19-BCMA Dual-Target CAR T-Cell Therapy (Beijing Gao Boren Hospital) | Phase 1 Clinical | Beijing Gao Boren Hospital Co Ltd | Anemia, Hemolytic, Autoimmune; Lupus Erythematosus, Systemic; Multiple Sclerosis; Scleroderma, Systemic; Sjogren's Syndrome | Details | |
| IASO-206 | IASO206; IASO-206 | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Multiple Myeloma | Details |
| UCAR T-cell therapy (The Children'S Hospital, Zhejiang University School Of Medicine) | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases; Glomerulonephritis, IGA; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic | Details | |
| Fully-Human Anti-BCMA CAR therapy (NIH) | Phase 1 Clinical | National Cancer Institute | Multiple Myeloma | Details | |
| NPB5005-V283 | NPB5005-V283 | Phase 1 Clinical | Neomics Pharmaceuticals LLC | Multiple Myeloma | Details |
| CAR19-BCMA dual-target CAR-T cell therapy (Tahoe Chunyu Biotechnology) | Phase 1 Clinical | Hebei Tahoe Chunyu Biotechnology Co Ltd | Multiple Myeloma | Details | |
| TPST-2003 | TPST-2003 | Phase 1 Clinical | Factor Bioscience Inc | Multiple Myeloma | Details |
| Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells therapy (Rui Therapeutics) | KN-3601; KN3601 | Phase 1 Clinical | Shenzhen Rui Therapeutics Co Ltd | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic; Nephrosis; Scleroderma, Systemic; Sjogren's Syndrome | Details |
| KT-501 | KT501; KT-501 | Phase 1 Clinical | Kali Therapeutics Inc | Arthritis, Rheumatoid | Details |
| Fully Human BCMA-Targeted Chimeric Antigen Receptor Autologous T-Cell therapy (Institute of Hematology & Blood Diseases Hospital) | CT103d | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Allogeneic, Umbilical Cord Blood-derived, Dual-targeting BCMA/CD19 CAR-T Therapy (Ucello) | Phase 1 Clinical | Ucello Therapeutics Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details | |
| QM-103 | QM-103; QM103 | Phase 1 Clinical | Beijing Qimai Yonghua Biotechnology Co Ltd | Multiple Myeloma | Details |
| RN-1201 | RN-1201; RN1201 | Phase 1 Clinical | The First Affiliated Hospital Of Soochow University | Thrombocytopenia | Details |
| OriV-508 | OriV508; OriV-508 | Phase 1 Clinical | Wuhan Medical Care Center For Women And Children | Lymphoma, Non-Hodgkin; Multiple Myeloma | Details |
| Meta10-BCMA | Meta10-BCMA | Phase 1 Clinical | Anhui Provincial Hospital | Immunoglobulin Light-chain Amyloidosis; Leukemia, Plasma Cell; Multiple Myeloma | Details |
| SL-0439 | SL0439; SL-0439 | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Multiple Myeloma | Details |
| RN-1101 (Rui Therapeutics) | RN-1101 | Phase 1 Clinical | Shenzhen Rui Therapeutics Co Ltd | Lymphoma, B-Cell; Multiple Myeloma | Details |
| CAR19BCMA-T cells therapy(The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital)) | Phase 1 Clinical | The Fifth Medical Center Of Pla General Hospital (Formerly 307 Hospital) | Neoplasms, Plasma Cell | Details | |
| Anti-CD19/BCMA CAR NK cells therapy(The Children's Hospital of Zhejiang University School of Medicine) | KN5601; KN-5601 | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Arthritis; Autoimmune Diseases; Glomerulonephritis, IGA; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Mucocutaneous Lymph Node Syndrome; Nephrosis; Rheumatic Diseases | Details |
| RD06-05 | RD06-05 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd | Anemia, Hemolytic, Autoimmune; Anti-Glomerular Basement Membrane Disease; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Encephalitis; Evans syndrome; Glomerulonephritis; Graves Disease; Lung Diseases, Interstitial; Lupus Erythematosus, Systemic; Multiple Sclerosis; Myasthenia Gravis; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic; Scleroderma, Systemic | Details |
| CT-0596 | CT-0596; CT0596 | Phase 1 Clinical | Carsgen Biomedicine (Shanghai) Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| 68Ga-BC1 | 68Ga-BC1 | Phase 1 Clinical | The First Affiliated Hospital Of Beijing University | Multiple Myeloma; Neoplasms, Plasma Cell | Details |
| UF-KURE-BCMA CAR-T Cells therapy(University Hospitals Cleveland Medical Center) | Phase 1 Clinical | University Hospitals Cleveland Medical Center | Multiple Myeloma | Details | |
| ESO-T01 | ESO-T01 | Phase 1 Clinical | EsoBiotec SA | Multiple Myeloma | Details |
| REVO-UWD-00B | REVO-UWD-00B; UWD-00B | Phase 1 Clinical | Wondercel Therapeutics Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA/CD70 CAR-T cells therapy(The Children'S Hospital, Zhejiang University School Of Medicine) | Phase 1 Clinical | The Children'S Hospital, Zhejiang University School Of Medicine | Lupus Erythematosus, Systemic; Nephrosis | Details | |
| PRG-2311 | PRG-2311 | Phase 1 Clinical | Shenzhen Pregene Biopharma Co Ltd | Immunoglobulin G4-Related Disease; Lupus Nephritis | Details |
| BZE-2204 | BZE2204; BZE-2204 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Multiple Myeloma; Myositis; Purpura, Thrombocytopenic, Idiopathic | Details |
| OL-101 | OL-101 | Phase 1 Clinical | Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
| Anti-CD19/BCMA CAR T-cell therapy(YaKe Biotechnology) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Lupus Erythematosus, Systemic; Lupus Nephritis | Details | |
| QLS-4131 | QLS-4131; QLS4131 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma | Details |
| Zirconium-89 belantamab | 89Zr-GSK2857914 | Phase 1 Clinical | Glaxosmithkline Plc | Multiple Myeloma; Neoplasms | Details |
| RD-140 | RD140 | Phase 1 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| BCMA CAR-NK (Hrain Biotechnology) | HR012 | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lupus Erythematosus, Systemic | Details | |
| SYS-6020 | SYS6020; SYS-6020 | Phase 1 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis | Details |
| KLN-1010 | KLN-1010 | Phase 1 Clinical | Kelonia Therapeutics Inc | Blood Protein Disorders; Hemostatic Disorders; Immune System Diseases; Immunoproliferative Disorders; Lymphoproliferative Disorders; Multiple Myeloma; Neoplasms; Paraproteinemias; Vascular Diseases | Details |
| The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) | FKC-288; FKC288 | Phase 1 Clinical | Nanjing University School Of Medicine | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Glomerulonephritis, Membranous; Immunoglobulin G4-Related Disease; Lupus Nephritis | Details |
| YKST-02 | YKST02; YKST-02 | Phase 1 Clinical | Excyte Biopharma Ltd | Multiple Myeloma | Details |
| BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) | BMS-986453 | Phase 1 Clinical | Juno Therapeutics Inc | Multiple Myeloma | Details |
| SIM-0500 | SIM-0500; SIM0500 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Bone Marrow Neoplasms; Multiple Myeloma | Details |
| Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Multiple Myeloma | Details | |
| BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics) | CBG-002 CAR-T | Phase 1 Clinical | Carbiogene Therapeutics Co Ltd | Multiple Myeloma | Details |
| BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) | SWK001; SWK-001 | Phase 1 Clinical | Hunan Siweikang Pharmaceutical Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA CAR T (Nanjing Kati Medical Technology) | Phase 1 Clinical | Nanjing Kati Medical Technology Co Ltd | Multiple Myeloma | Details | |
| Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) | Phase 1 Clinical | Actavis Inc, Eugia Pharma Specialities Ltd | Multiple Myeloma | Details | |
| LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) | Phase 1 Clinical | Multiple Myeloma | Details | ||
| BRL-302 | BRL-302 | Phase 1 Clinical | BRL Medicine Inc | Autoimmune Diseases; Lupus Nephritis; Multiple Sclerosis; Myasthenia Gravis; Neuromyelitis Optica; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| MCARH-125 | MCARH-125 | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Multiple Myeloma | Details |
| ISB-2001 | ISB-2001; ABBV-2001 | Phase 1 Clinical | Ichnos Sciences Sa | Multiple Myeloma | Details |
| OriC-321 | OriC-321; Ori-C-321 | Phase 1 Clinical | OriCell Therapeutics Co Ltd, Zhejiang University | Multiple Myeloma | Details |
| HY-027 | HY-027 | Phase 1 Clinical | Juventas Cell Therapy Ltd | Multiple Myeloma | Details |
| MEDI-2228 | MEDI-2228 | Phase 1 Clinical | Medimmune Llc | Multiple Myeloma | Details |
| IBI-346 | IBI-346 | Phase 1 Clinical | Multiple Myeloma | Details | |
| BCMA-NKE | BCMA-NKE | Phase 1 Clinical | Bristol-Myers Squibb Company | Multiple Myeloma | Details |
| KJ-C2111 | CT-0590; KJ-C2111 | Phase 1 Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| PHE-885 | PHE-885 | Phase 1 Clinical | Novartis Pharma Ag | Hematologic Neoplasms; Multiple Myeloma | Details |
| MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
| ALLO-605 | ALLO-605; ALLO605 | Phase 1 Clinical | Cellectis Sa, Overland Pharmaceuticals (Shanghai) Co Ltd | Multiple Myeloma | Details |
| AUTO-8 | AUTO-8 | Phase 1 Clinical | Autolus Therapeutics Plc | Multiple Myeloma | Details |
| Cizutamig | EMB-06; CND-106; CN106 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Colitis, Ulcerative; Food Hypersensitivity; Graves Ophthalmopathy; Hypersensitivity, Immediate; Lupus Erythematosus, Systemic; Multiple Myeloma; Myasthenia Gravis; Pemphigus; Scleroderma, Systemic | Details |
| CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Multiple Myeloma | Details | |
| JWCAR129 | JWCAR129; JWCAR-129 | Phase 1 Clinical | Suzhou Yaomingjunuo Biotechnology Co Ltd | Multiple Myeloma | Details |
| Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) | Phase 1 Clinical | Chongqing Xinqiao Hospital | Multiple Myeloma | Details | |
| BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) | LCAR-BCX | Phase 1 Clinical | Multiple Myeloma | Details | |
| CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd, Zhejiang University | Autoimmune Diseases; Lupus Erythematosus, Systemic; Lupus Nephritis; Lymphoma, Non-Hodgkin; Multiple Myeloma; Nephritis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Scleroderma, Systemic; Sjogren's Syndrome | Details | |
| C-4-29 | Phase 1 Clinical | Chongqing Precision Biotechnology Co Ltd | Carcinoma, Renal Cell; Lupus Erythematosus, Systemic; Multiple Myeloma | Details | |
| CC-98633 | CC-98633 | Phase 1 Clinical | Celgene Corp | Multiple Myeloma | Details |
| Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) | Clinical | Wuhan BioRaid Biotechnology Co Ltd | Hematologic Neoplasms | Details | |
| Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) | Clinical | Huazhong University Of Science And Technology | Multiple Myeloma | Details | |
| ECAR-01 | ECAR-01; ECAR01 | Clinical | Anhui Provincial Hospital | Autoimmune Diseases | Details |
| CT-059X | CT-059X; CT059X | Clinical | CARsgen Therapeutics Holdings Ltd | Leukemia, Plasma Cell; Multiple Myeloma | Details |
| Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells therapy(Acellytron Therapeutics) | ACT-001(Acellytron Therapeutics) | Clinical | Acellytron Therapeutics | Multiple Myeloma | Details |
| Anti-BCMA chimeric antigen receptor natural killer cell therapy (Hangzhou Cheetah Cell Therapeutics) | Clinical | Multiple Myeloma | Details | ||
| PD-1Ab21-BCMACAR-T (CD biopharma) | CD-003; CD-203 | Clinical | CD (Suzhou) Biopharma Co Ltd | Multiple Myeloma | Details |
| BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics) | UTAA17 | Clinical | Persongen Biotherapeutics (Suzhou) Co Ltd | Multiple Myeloma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Belantamab mafodotin | GSK-2857916; GSK2857916 | Approved | Glaxosmithkline Plc | BLENREP | United States | Multiple Myeloma | Glaxosmithkline Plc | 2020-08-05 | Amyloidosis; Blood Protein Disorders; Bone Marrow Neoplasms; Corneal Diseases; Immunoglobulin Light-chain Amyloidosis; Lymphoma, B-Cell; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Paraproteinemias; Plasmablastic Lymphoma; Plasmacytoma | Details |
| Idecabtagene vicleucel | bb-2121 | Approved | Genetix Biotherapeutics Inc | Abecma | United States | Multiple Myeloma | Celgene Corp | 2021-03-26 | Multiple Myeloma | Details |
| Zevorcabtagene Autoleucel | CT-053-CARsgen | Approved | Carsgen Biomedicine (Shanghai) Co Ltd | 赛恺泽 | Mainland China | Multiple Myeloma | Kaixing Life Technology (Shanghai) Co Ltd | 2024-02-23 | Multiple Myeloma | Details |
| Equecabtagene Autoleucel | CT-103A; CT103A; IBI-326 | Approved | Innovent Biologics(Suzhou) Co Ltd, Nanjing Iaso Biotherapeutics Co Ltd | 福可苏, FUCASO | Mainland China | Multiple Myeloma | Nanjing Xunlu Biomedicine Co Ltd | 2023-06-30 | Autoimmune Diseases; Autoimmune Diseases of the Nervous System; Encephalitis; Immunoglobulin Light-chain Amyloidosis; Lupus Erythematosus, Systemic; Lupus Nephritis; Multiple Myeloma; Multiple Sclerosis; Muscular Diseases; Myasthenia Gravis; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Myositis; Neuromyelitis Optica; POEMS Syndrome; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Details |
| Teclistamab | JNJ-64007957; JNJ-64007959; JNJ-7957 | Approved | Genmab A/S, Johnson & Johnson Innovative Medicine | TECAYLI, TECVAYLI, 泰立珂 | EU | Multiple Myeloma | Janssen-Cilag International Nv | 2022-08-23 | Hematologic Diseases; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Plasmablastic Lymphoma; Smoldering Multiple Myeloma | Details |
| Ciltacabtagene autoleucel | JNJ-4528; LCAR-B38M; JNJ-68284528 | Approved | Carvykti, 卡卫荻 | United States | Multiple Myeloma | Nanjing Legend Biotechnology Co Ltd, Janssen Research & Development Llc | 2022-02-28 | Multiple Myeloma | Details | |
| Linvoseltamab | REGN-5458 | Approved | Regeneron Pharmaceuticals Inc | Lynozyfic | EU | Multiple Myeloma | Regeneron Ireland Designated Activity Company | 2025-04-23 | Food Hypersensitivity; Immunoglobulin Light-chain Amyloidosis; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Renal Insufficiency, Chronic; Smoldering Multiple Myeloma | Details |
| Elranatamab | PF‑3135; RN-613; PF-06863135 | Approved | Pfizer Inc | Elrexfio, ELREXFIO™, ELREXFIO | United States | Multiple Myeloma | Pfizer Inc | 2023-08-14 | Anemia, Hemolytic, Autoimmune; Bone Marrow Neoplasms; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Smoldering Multiple Myeloma; Spinal Cord Diseases | Details |
Product Reviews
T***d2025-06-13
0People LikeGroup used this product in a TE experiment on the MSD platform. Achieved a STD Curve range that was adequate for assay needs.- S***i2025-01-23 1People LikeWe have repurchased this item dozens of time. This product is very effective for flow cytometry and we use it to help detect our BCMA CAR-T product.
- J***y2024-10-29 0People LikeProduct utilized for routine FACS flow cytometry analyses of T cells cultured in vitro. The material comes in efficient packaging, and comes in quantities that facilitate reliable mid- to long-term stock. There have not appeared to be any signs of problems with failed non-specific binding blockage. The material has proven to be reliable in performance over moderate lengths of storage time, and after experiencing some variable temperature exposure.
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
Contact Us
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8